Last edition
News about "Artificial Intelligence-assisted Structure-Based D"
Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity
Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.
Artificial Intelligence-assisted Structure-Based D | 17/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members